|
1
|
Wang Y, Dai W, Chu X, Yang B, Zhao M and
Sun Y: Metformin inhibits lung cancer cells proliferation through
repressing microRNA-222. Biotechnol Lett. 35:2013–2019. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Col NF, Ochs L, Springmann V, Aragaki AK
and Chlebowski RT: Metformin and breast cancer risk: A
meta-analysis and critical literature review. Breast Cancer Res
Treat. 135:639–646. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Currie CJ, Poole CD and Gale EA: The
influence of glucose-lowering therapies on cancer risk in type 2
diabetes. Diabetologia. 52:1766–1777. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wright JL and Stanford JL: Metformin use
and prostate cancer in Caucasian men: Results from a
population-based case-control study. Cancer Causes Control.
20:1617–1622. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Memmott RM, Mercado JR, Maier CR, Kawabata
S, Fox SD and Dennis PA: Metformin prevents tobacco
carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila).
3:1066–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smiechowski BB, Azoulay L, Yin H, Pollak
MN and Suissa S: The use of metformin and the incidence of lung
cancer in patients with type 2 diabetes. Diabetes Care. 36:124–129.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nie SP, Chen H, Zhuang MQ and Lu M:
Anti-diabetic medications do not influence risk of lung cancer in
patients with diabetes mellitus: A systematic review and
meta-analysis. Asian Pac J Cancer Prev. 15:6863–6869. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thomas A, Chen Y, Yu T, Jakopovic M and
Giaccone G: Trends and characteristics of young non-small cell lung
cancer patients in the United States. Front Oncol. 5:1132015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu M, Cai X, Yu W, Lv C and Fu X:
Clinical significance of age at diagnosis among young non-small
cell lung cancer patients under 40 years old: A population-based
study. Oncotarget. Oct 26–2015.(Epub ahead of print).
|
|
10
|
Pinhas-Hamiel O and Zeitler P: Clinical
presentation and treatment of type 2 diabetes in children. Pediatr
Diabetes. 8(Suppl 9): 16–27. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
National Institute for Health and Care
Excellence: Diabetes (type 1 and type 2) in children and young
people: Diagnosis and management. London, UK: 2015.http://www.nice.org.uk/guidance/ng18/resources/diabetes-type-1-and-type-2-in-children-and-young-people-diagnosis-and-management-1837278149317Accessed.
February 05–2015
|
|
12
|
Sakoda LC, Ferrara A, Achacoso NS, Peng T,
Ehrlich SF, Quesenberry CP Jr and Habel LA: Metformin use and lung
cancer risk in patients with diabetes. Cancer Prev Res (Phila).
8:174–179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mack JW, Cronin A, Fasciano K, Block SD
and Keating NL: Cancer treatment decision-making among young adults
with lung and colorectal cancer: A comparison with adults in middle
age. Psychooncology. Sep 2–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Skuladottir H, Hirsch FR, Hansen HH and
Olsen JH: Pulmonary neuroendocrine tumors: Incidence and prognosis
of histological subtypes. A population-based study in Denmark. Lung
Cancer. 37:127–135. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun Z, Aubry MC, Deschamps C, et al:
Histologic grade is an independent prognostic factor for survival
in non-small cell lung cancer: An analysis of 5018 hospital- and
712 population-based cases. J Thorac Cardiovasc Surg.
131:1014–1020. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jatoi A, Qi Y, Wampfler JA, Busta AJ, Yang
P and Mandrekar S: The purported effects of alcohol on appetite and
weight in lung cancer patients. Nutr Cancer. 63:1251–1255. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deng B, Cassivi SD, de Andrade M, et al:
Clinical outcomes and changes in lung function after segmentectomy
versus lobectomy for lung cancer cases. J Thorac Cardiovasc Surg.
148:1186–1192. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang P, Cheville AL, Wampfler JA, Garces
YI, Jatoi A, Clark MM, Cassivi SD, Midthun DE, Marks RS, Aubry MC,
et al: Quality of life and symptom burden among long-term lung
cancer survivors. J Thorac Oncol. 7:64–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
O'Reilly KE, Rojo F, She QB, Solit D,
Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al:
mTOR inhibition induces upstream receptor tyrosine kinase signaling
and activates Akt. Cancer Res. 66:1500–1508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Edge S, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: American Joint Committee on Cancer: AJCC
Cancer Staging Manual. Springer. New York: 2010.
|
|
21
|
Libutti SK: Therapy: Blockade of IGF-1R -
not effective in neuroendocrine tumours. Nat Rev Endocrinol.
9:389–390. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vlotides G, Tanyeri A, Spampatti M,
Zitzmann K, Chourdakis M, Spttl C, Maurer J, Nölting S, Göke B and
Auernhammer CJ: Anticancer effects of metformin on neuroendocrine
tumor cells in vitro. Hormones. 13:498–508. 2014.PubMed/NCBI
|
|
23
|
Gallagher EJ and LeRoith D: Obesity and
diabetes: The increased risk of cancer and cancer-related
mortality. Physiol Rev. 95:727–748. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tseng CH: Diabetes but not insulin
increases the risk of lung cancer: A Taiwanese population-based
study. PLoS One. 9:e1015532014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maxwell JE, O'Dorisio TM, Bellizzi AM and
Howe JR: Elevated pancreatic polypeptide levels in pancreatic
neuroendocrine tumors and diabetes mellitus: Causation or
association? Pancreas. 43:651–656. 2014. View Article : Google Scholar : PubMed/NCBI
|
